Archives
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
TRAF and TRAF were initially identified as tumor
2019-08-17

TRAF1 and TRAF2 were initially identified as tumor necrosis factor receptor 2 (TNRF2)-associated components, TRAF4 was overexpressed in breast carcinoma cells, whereas TRAF3, TRAF5 and TRAF6 were discovered by their interaction with specific domains in the cytoplasmic tails of trans-membrane recepto
-
Even though Et modification of DNA delayed the progress of
2019-08-17

Even though Et743 modification of DNA delayed the progress of the translocating enzyme significantly, it did not trap RecBCD on DNA, nor did it alter the activity of the enzyme significantly. Under catalytic conditions, no loss of enzyme activity was observed (Table 2), nor were stable unwinding int
-
DGK is also involved in cell
2019-08-17

DGKδ is also involved in cell differentiation. Previously, to investigate the physiological roles of DGKδ, DGKδ-deficient mice have been generated. On the basis of the analysis of DGKδ-deficient mice, Crotty et al. reported that DGKδ regulates the epidermal growth factor receptor (EGFR) pathway by a
-
Next the BE obtained for the different
2019-08-17

Next, the BE obtained for the different complexes were evaluated. From the BE obtained from our MD simulations, a very good binder can be differentiated from a very weak binder (−11.85 kcal/mol for MTX vs. −6.74 and −3.61 kcal/mol for compounds 14b and 15c, respectively) but ligands with similar bin
-
Quercetin competitively inhibited BFC activity in human reco
2019-08-17

Quercetin competitively inhibited BFC activity in human recombinant cDNA-expressed CYP3A4 with Ki=15.4±1.52μM, and myricetin noncompetitively with Ki=74.6±7.99μM (Fig. 4). The degree of inhibition by quercetin was not affected by a pre-incubation step and was similar in the microsomes from both gend
-
van Linden et al developed a
2019-08-17

van Linden et al. developed a comprehensive guide that describes drug and ligand binding to more than 1200 human and mouse protein kinase domains [77]. Their KLIFS (kinase–ligand interaction fingerprint and structure) directory includes an alignment of 85 potential ligand binding-site residues occur
-
br Conflicts of interest br Acknowledgements br Lung cancer
2019-08-16

Conflicts of interest Acknowledgements Lung cancer continues to be the leading cause of cancer deaths in the US and worldwide., Non–small-cell lung cancer (NSCLC) remains the predominant form of lung cancer (approximately 85%)., With some improvements in surgical techniques and combined ther
-
Lomustine The genetic basis of resistance to dieldrin
2019-08-16

The genetic basis of resistance to dieldrin has been described for several insect species as a mutation in the transmembrane domain II of the GABA-Cl or rdl (resistance to dieldrin) gene (ffrench-Constant et al., 2004; Bass et al., 2004; Du et al., 2005). A mutation in the GABA-Cl gene was found at
-
STF-62247 formula br Experiments br Numerical simulations b
2019-08-16

Experiments Numerical simulations Discussion Conclusions By large-caliber PELE with various d/D against RHA plate at low velocity of 415 m s−1, impact experiments against 30 mm RHA target were carried out. Numerical simulations were also conducted to monitor progress of PELE expansion an
-
The mRNA expression of asEP studied by RT
2019-08-16

The mRNA expression of asEP4 studied by RT-PCR shows that EP4 is expressed in many different tissues in Atlantic salmon which is comparable to other species (Sugimoto and Narumiya, 2007) although some distinct differences are present. For example, in mice the expression of EP4 receptor was found to
-
Based on the similar activities of Rad
2019-08-16

Based on the similar activities of Rad6p and Cdc34p (i.e., both are E2 ub-conjugating enzymes) on ubiquitinylation of p33 replication protein, we propose that Rad6p and the plant Ubc2p mono- and bi-ubiquitinate the viral replication proteins in order to facilitate the recruitment of the cellular ESC
-
hnRNP E functions in a
2019-08-16

hnRNP E1 functions in a number of mRNA regulatory processes including transcription [74], [75], splicing [7], [74], [76], [77] and translation [6], [8], [69], [78], interacting with RNAs through CU rich regions such as the differentiation control element (DICE) and the TGFβ activated translation (BA
-
RDH belongs to C family of the short
2019-08-16

RDH10 belongs to 16C family of the short-chain dehydrogenase/reductase (SDRs) superfamily of proteins [12], [13]. Notably, in human genome adjacent to the gene encoding RDH10 on chromosome 8 are located two other genes encoding members of the SDR16C family: retinol dehydrogenase epidermal 2 (RDHE2,
-
The lungs dissected from week mice were cut into
2019-08-16

The lungs dissected from 4–5-week mice were cut into small pieces and then immersed in Dulbecco\'s modified Eagle\'s medium (Invitrogen, Carlsbad, CA) containing collagenase II (2 mg/ml), trypsin (2.5 mg/ml), Dnase I (2 mg/ml), penicillin (100 U/ml), and streptomycin (100 μg/ml) for 12 hours at 37 °
-
Our recent discovery M P H R A S
2019-08-16

Our recent discovery (M.P., H.R., A.S.) of a highly selective and in vivo active DDR1 small-molecule inhibitor provides evidence that DDR1 is a druggable pharmaceutical target, and some details of our efforts are provided below. To avoid the repurposing of known kinase inhibitor structural motifs, w
15567 records 974/1038 page Previous Next First page 上5页 971972973974975 下5页 Last page